SCHEMBL25819260

SCHEMBL25819260

CCCC1CCN(NC(=O)OC(C)(C)C)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
KMT2A Q03164 2/20 0.52
MEN1 O00255 1/20 0.39
TSHR P16473 1/20 0.39
CTSK P43235 3/20 0.38
DRD2 P14416 3/20 0.36
CKS1B P61024 1/20 0.36
SKP1 P63208 1/20 0.36
SKP2 Q13309 1/20 0.36
CA1 P00915 2/20 0.36
CA12 O43570 1/20 0.36
CA7 P43166 1/20 0.36
CA14 Q9ULX7 1/20 0.36
EPHX1 P07099 1/20 0.35
KDM4E B2RXH2 1/20 0.35
PKM P14618 1/20 0.35
GPR119 Q8TDV5 1/20 0.35
CTSS P25774 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16419549 0.89 KMT2A (0.40) ALDH1A1KMT2AMEN1TSHRCTSK
SCHEMBL7441833 0.88 ACACB (0.40) ALDH1A1KMT2AMEN1TSHRCTSK
SCHEMBL5914370 0.86 KMT2A (0.39) ALDH1A1KMT2AMEN1TSHRCTSK
SCHEMBL15009171 0.86 NR1H2 (0.42) ALDH1A1KMT2AMEN1TSHRCTSK
SCHEMBL3625257 0.84 ACACB (0.40) ALDH1A1KMT2AMEN1TSHRCTSK
SCHEMBL30965680 0.82 EPHX1 (0.40) ALDH1A1KMT2AMEN1TSHRCTSK
SCHEMBL19209517 0.81 GPR119 (0.36) ALDH1A1KMT2AMEN1TSHRCTSK
SCHEMBL27349219 0.80 CTSK (0.41) ALDH1A1KMT2AMEN1TSHRCTSK
SCHEMBL15654440 0.80 CHRM2 (0.41) ALDH1A1KMT2AMEN1TSHRCTSK
SCHEMBL14761911 0.79 ALDH1A1 (0.34) ALDH1A1KMT2AMEN1TSHRCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-20230242541-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-08-03 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 ALDH1A1 4008/4885KMT2A 1840/4885MEN1 3403/4885
US-20230242541-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 ALDH1A1 4008/4885KMT2A 1840/4885MEN1 3403/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 ALDH1A1 2752/4885KMT2A 1115/4885MEN1 2443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.